

A Multi-Modal Approach to **Gynecologic Cancer** **Screening & Detection**

Transforming Women's Health with an Innovative Solution

With a focus on women's health, ASPIRA® offers **targeted and comprehensive genetic testing options** for Hereditary breast and gynecologic cancers to help guide medical management.




Novel Approach to Gynecologic Cancer Risk Assessment

- ✓ Over 10 years of expertise in Ovarian Cancer Risk assessment and Pelvic mass management
- ✓ Cutting edge bioinformatics for analysis and data management
- ✓ Incorporation of genetic testing for hereditary cancer syndrome risk assessment
- ✓ Laboratory Research focused on innovation and discovery

Genetic Testing Options to Provide Personalized Care

On average, **1 in 78 women will develop ovarian cancer in her lifetime.** By the time this cancer is detected, it is often at an advanced stage. Women with a hereditary cancer syndrome can have up to a 67% chance to develop ovarian cancer. Knowing a woman's background risk for cancer is therefore the best way to determine an appropriate screening and surveillance strategy. **Genetic testing** is part of establishing this background risk.



Genetic testing may not be appropriate for all women. **This screening tool helps determine which of your patients may benefit from genetic testing.**

A sample of the Cancer History Questionnaire form. The form is titled "Cancer History Questionnaire" and includes the instruction "Please answer the questions below to the best of your ability." It contains two main sections for "Do you have a personal history of a history of:" and "Do you have a family history of other relatives:". Each section lists various cancer types (Breast, Ovarian, Pancreatic, Colorectal, etc.) and includes checkboxes for "Yes", "No", "Unknown", and "If Yes, please list (Date, what gene and location) (if known)". The form also includes a section for "Has anyone in your family had genetic testing for hereditary cancer?" and a section for "If yes, please list (Date, what gene and location) (if known)". The form is branded with the ASPIRA GENETIX logo and contact information.

With a focus on gynecologic cancers, ASPIRA offers both targeted and comprehensive genetic testing options

ASPIRA GENETIX Testing Options

BRCA1 & BRCA2

Genes Tested:

BRCA1, BRCA2

Patient Considerations for Testing:

BRCA1 & BRCA2 are genes with a well-established association with increased risk for breast and ovarian cancers along with other cancers like pancreatic and prostate.

Targeted Gynecologic Panel

Genes Tested:

ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MSH2(mono/biallelic), MSH6, MRE11A, NBN, NFI, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53

Patient Considerations for Testing:

Including BRCA1 & BRCA2, the genes in the targeted panel include High to Moderate risk genes associated with hereditary breast and ovarian cancer, including syndromic genes with elevated risk of HBOC (such as Lynch Syndrome). Patients with a personal or family history of breast and/or ovarian cancer without a known family history of BRCA1 or BRCA2 mutations may benefit from this option.

Comprehensive Gynecologic Panel

Genes Tested:

ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, FANCC, MLH1, MRE11(A), MSH2(mono/biallelic), MSH6, MUTYH, NBN, NFI, NTHL1 (mono/biallelic), PALB2, POLE, POLD1, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL (WRN), SDHB, SDHD, SMARCA4, STK11, TP53, XRCC2

Patient Considerations for Testing:

Along with BRCA1 & BRCA2, the genes in the comprehensive panel include those with strong associations with hereditary breast and ovarian cancer as well as some genes associated with uterine & endometrial cancer risk. Also included on the panel are newer evidence genes where there is a suspicion of associated gynecologic cancer risk. Patients with a family history of breast, ovarian and/or endometrial cancer without a known family history of BRCA1 or BRCA2 mutations may benefit from this option.

Gynecologic Cancer Predisposition Syndromes Covered

	BRCA1/ BRCA2	Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)	Peutz- Jeghers Syndrome (STK11)	Li-Fraumeni Syndrome (TP53)	Cowden Syndrome (PTEN)	New Evidence Genes (FANCC, MRE11, NFI, NTHL1)
BRCA1/BRCA2	✓					
Targeted Gynecologic Panel	✓	✓	✓	✓	✓	
Comprehensive Gynecologic Panel	✓	✓	✓	✓	✓	✓

4 Reasons Why Your Patient Should Have Genetic Testing

- 1 Help establish background risk for hereditary cancer
- 2 Identify other reproductive cancer risks
- 3 Inform appropriate screening and management for patients with a positive test result
- 4 Determine the risk to other family members

Genetic Testing Process

ASPIRA reports genetic test results in 2-3 weeks.

1

Submit blood or saliva to ASPIRA for testing.

2

ASPIRA analyzes specific genes known to increase the risk for gynecologic cancer.

3

ASPIRA reports your hereditary cancer risk based on the genes analyzed.*

4

Review results and any recommended management recommendations.

5

Discuss relevant results and recommendations with patient.

*Our Lab is CLIA certified and CAP accredited in all 50 states and meets the standards of diagnostic testing. All specimens are processed at our US laboratory. All data analysis is performed on private US server centers.

Pre and Post Test Genetic Counseling

Personalized Genetic expertise for your patients

PRE-TEST CONSULTATION

Talk with a genetic expert by phone or video once your test is ordered. We review personal and family health history, answer any questions you may have, and determine if you meet eligibility for pre-test authorization.

RESULTS CONSULTATION

Review test results with a genetic counselor or medical geneticist. During this phone or video session, you are provided an opportunity to discuss the results of the test and their implications.

Our goal at ASPIRA is to provide patients with **simple and transparent** billing policies.

PROGRAM DETAILS

Insurance Billing

ASPIRA® accepts and bills for most insurances.

Our billing experts will work directly with your patients insurance to determine coverage.

Payment Options

We offer financial assistance and/or payment plans (for those who qualify) for costs associated with testing provided by ASPIRA®.

Will my patient receive a bill?

Yes, your patient may receive a bill for any testing costs that are not covered by insurance or where they have not met contribution requirements (i.e. deductibles, copays, coinsurance etc.).

Upon receipt of either an invoice or an EOB patients can call us to discuss options.

Call 866.927.7472 or email billing@aspirawh.com



1. ACOG Practice Bulletin Number 182, September 2017

2. Lancaster, Johnathan M. et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. *Gynecologic Oncology*, Volume 136, Issue 1, 3 - 7